Results 111 to 120 of about 17,756 (247)

Defining a Therapeutic Window for Venetoclax in Post‐Transplant Maintenance Therapy for High‐Risk Acute Myeloid Leukemia and Myelodysplastic Syndromes

Hematological Oncology, Volume 44, Issue 5, September 2026.
ABSTRACT Patients with high‐risk acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) continue to face a substantial risk of relapse after allogeneic hematopoietic stem cell transplantation (allo‐HSCT), which remains a leading cause of treatment failure.
Cuicui Lyu, Tianle Xie, Yedi Pu, Xianshuang Luan, Xia Xiao, Mingfeng Zhao, Hairong Lyu   +6 more
wiley   +1 more source

Osteoarthritis: An Immuno‐Inflammatory Disease‐Mechanisms of Immune Cell Dysregulation and Potential Therapeutic Strategies

Med Research, Volume 2, Issue 3, Page 498-521, September 2026.
This review summarizes the immuno‐inflammatory mechanisms driving the pathogenesis of osteoarthritis (OA), extending beyond the traditional view of OA as a purely degenerative disease to incorporate immune cell infiltration, inflammatory factor release, and the formation of a chronic low‐grade inflammatory microenvironment.
Qingqiang Lei, Xiaoxian Lou, Xu Su, Shubao Liu, Yanli Tong, Jie Chen, Xuerui Chen, Wenjun Mao, Hui Yu, Liangbin Lin   +9 more
wiley   +1 more source

Chimeric antigen receptors against CD33/CD123 antigens efficiently target primary acute myeloid leukemia cells in vivo

, 2014
As significant numbers of acute myeloid leukemia (AML) patients are still refractory to conventional therapies or experience relapse, immunotherapy using T cells expressing chimeric antigen receptors (CARs) might represent a valid treatment option.
K Rouault-Pierre, Bonnet, D., I Pizzitola, Anjos-Afonso, Fernando, Biagi, E., A Biondi, Pizzitola, I., O Spinelli, F Lassailly, F Anjos-Afonso, Tettamanti, S., Spinelli, O., S Tettamanti, Rouault-Pierre, K., Lassailly, F., E Biagi, Biondi, A., D Bonnet   +17 more
core   +1 more source

RELATIONSHIP BETWEEN THE EXPRESSION OF CD34, CD123 AND MYELOPEROXIDASE MARKERS BY FLOW CYTOMETRY AND RESPONSE TO INDUCTION THERAPY IN ACUTE MYELOID LEUKEMIA

The Iraqi Journal of Medical Sciences, 2016
Background:Different immunophenotypic markers were found to be related to the prognosis of acute myeloid leukemia. Among them are CD34, CD123 and myeloperoxidase.
Faez Sh. Almohsen, Subh S. Al-Mudallal
doaj   +4 more sources

Recent developments in the treatment of blastic plasmacytoid dendritic cell neoplasm

Therapeutic Advances in Hematology, 2019
Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a clinically aggressive hematologic malignancy derived from precursors of dendritic cells and involves most frequently the skin, bone marrow and lymph nodes. Diagnosis depends upon identification of
Minas P. Economides, Marina Konopleva, Naveen Pemmaraju   +2 more
doaj   +1 more source

IL‐33 Drives Inflammatory Changes and Extracellular Trap Formation in Eosinophils Involving Oxidised LDL and Complement Pathways

Allergy, Volume 81, Issue 9, Page 3171-3184, September 2026.
IL‐33 induces inflammatory gene signatures in eosinophils, characterised by the upregulation of cell surface markers, inflammatory mediators and regulatory factors, all of which were also observed in nasal polyp‐derived eosinophils. Ox‐LDL and complement fragments (C3a and C5a) promote eosinophil adhesion and survival.
Emiko Matsuyama, Jun Miyata, Takao Mochimaru, Ryuta Onozato, Yo Otsu, Hisashi Sasaki, Keeya Sunata, Shinichi Okuzumi, Katsunori Masaki, Hiroki Kabata, Keinosuke Hizuka, Yoshinori Hasegawa, Ryo Konno, Yusuke Kawashima, Makoto Arita, Shigeharu Ueki, Koichi Fukunaga   +16 more
wiley   +1 more source

Integrated Engineering of CAR‐T Cells for Solid Tumours

Cell Proliferation, Volume 59, Issue 9, September 2026.
Solid tumours pose multifactorial barriers including antigen heterogeneity, immunosuppressive microenvironment, and poor T‐cell trafficking, limiting CAR‐T efficacy compared to hematologic malignancies. Integrated engineering strategies are essential, combining logic‐gated receptors for precision, metabolic‐epigenetic reprogramming for resilience, and ...
Chao Yang, Tan Li, Ping He, Zhijie Zhao, Shenglong Li, Liming Wang   +5 more
wiley   +1 more source

Allogeneic hematopoietic cell transplantation as the standard of care for blastic plasmacytoid dendritic cell neoplasm in first complete remission

Hematology/Oncology and Stem Cell Therapy
Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare hematologic disorder derived from precursors of plasmacytoid dendritic cells, with a generally aggressive clinical course.
Mohamed A. Kharfan-Dabaja
doaj   +1 more source

Flow Cytometric Immune Profiling Enables Early Detection of Rejection in Islet Xenotransplantation

Xenotransplantation, Volume 33, Issue 5, September/October 2026.
ABSTRACT Background Islet xenotransplantation is a strategy for treatment of Type 1 Diabetes, but immune‐mediated rejection limits graft survival. This study investigated a strategy with flow cytometry–based immune monitoring to evaluate immunosuppressive therapy and provide indicators of graft rejection.
Huu Thanh Le, Erin Fuller, Lauen Joo, Evelyn J. Salvaris, Adwin Thomas, Yivee Chew, Min Hu, Francesco Ierino, Mark B. Nottle, Peter J. Cowan, Wayne J. Hawthorne   +10 more
wiley   +1 more source

Impact of scFv on Functionality and Safety of Third-Generation CD123 CAR T Cells

International audienceAbstract Chimeric antigen receptor (CAR) T cells express an extracellular domain consisting of a single-chain fragment variable (scFv) targeting a surface tumor-associated antigen. scFv selection should involve safety profiling with
Anna, François, Robinet, Eric, Fredon, Maxime, Mantion, Charles-Frédéric, Adotévi, Olivier, Chevrier, Sandrine, Deconinck, Eric, Caumartin, Julien, Biichlé, Sabeha, Godet, Yann, Garnache-Ottou, Francine, Bonnefoy, Francis, Daguidau, Etienne, Loustau, Maria, Galaine, Jeanne, Angelot-Delettre, Fanny, Boidot, Romain, Gonçalves-Venturelli, Mathieu, Saas, Philippe, Roussel, Xavier, Seffar, Evan, Poussard, Margaux, Renosi, Florian, Bôle-Richard, Elodie   +23 more
core   +1 more source